Considering the cholinergic neuron dysfunction in AD patients, acetylcholinesterase has been seen as a possible therapeutic target to increase concentrations of the neurotransmitter in the synaptic cleft, leading to its greater availability to act in nicotinic and muscarinic receptors. Here, ACHE is linked to Alzheimer disease.